<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="112649">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01910766</url>
  </required_header>
  <id_info>
    <org_study_id>CoQ10</org_study_id>
    <nct_id>NCT01910766</nct_id>
  </id_info>
  <brief_title>Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in Polycystic Ovary Syndrome</brief_title>
  <official_title>Combined Coenzyme Q10 and Clomiphene Citrate (CC) for Ovulation Induction in CC-resistant Patients With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective of the study was to evaluate the effect of combination of oral Coenzyme Q10
      (CoQ10), with clomiphene citrate (CC) for ovulation induction in CC-resistant polycystic
      ovary syndrome (PCOS).In a prospective controlled randomized trial performed in a university
      hospital and private practice setting. One hundred ten infertile women with PCOS resistant
      to CC were randomized to either combined CC/CoQ10 (51 patients, 82 cycles) or CC 150 mg/day
      alone (50 patients, 71 cycles) for ovulation induction in patients with CC-resistant PCOS.

      Main outcome measures: Number of follicles, serum E2, serum P, endometrial thickness,
      pregnancy rate (PR) and miscarriage rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No more details
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of ovulating patients</measure>
    <time_frame>1-2 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of pregnancies</measure>
    <time_frame>1-2 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of miscarriages</measure>
    <time_frame>1 month</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>Coenzyme Q10/CC group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention:
Coenzyme Q10 (CoQ10) and clomiphene citrate group (55 patients, 82 cycles) Patients in CoQ10/CC group took CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6, and CoQ10  Mepaco, Enshas Elraml, Sharkhia,  Egypt), in a dose of 60 mg 3 times day capsules orally starting on cycle day 2 and continued till the day of human chorionic gonadotropin (hCG) administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC alone group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention:
CC (Global Napi, Cairo, Egypt) 100 mg/day from cycle days 2-6</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Coenzyme Q10</intervention_name>
    <description>no more details</description>
    <arm_group_label>Coenzyme Q10/CC group</arm_group_label>
    <other_name>CC 100 mg/day 2-6 and CoQ10,60 mg 3 times day orally on day 2 till hCG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>clomiphene citrate</intervention_name>
    <arm_group_label>Coenzyme Q10/CC group</arm_group_label>
    <arm_group_label>CC alone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of PCOS based on the revised 2003 consensus on diagnostic criteria and
             long-term health risks related to PCOS (2003).

          -  All women were previously treated with 100 mg of CC daily for 5 days per cycle, for
             two to three cycles with persistent anovulation or ovulate with very thin endometrium
             &lt;5 mm at the time of hCG administration

        Exclusion Criteria:

          -  patients with hyperprolactinaemia,

          -  hypercorticism and

          -  thyroid dysfunction.

          -  patients receiving medications as cholesterol lowering drugs, as statins,
             beta-blockers, and tricyclic antidepressants
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Mansoura University Hospitals</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>35111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 29, 2013</lastchanged_date>
  <firstreceived_date>July 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mansoura University</investigator_affiliation>
    <investigator_full_name>ahmed M. badawy</investigator_full_name>
    <investigator_title>Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>pcos</keyword>
  <keyword>coenzymeQ10</keyword>
  <keyword>clomiphene citrate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Coenzyme Q10</mesh_term>
    <mesh_term>Ubiquinone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
